Your child may be able to participate in the START-UP Study if they:
Are 6 to under 12 years of age
Were diagnosed with atopic dermatitis at least 6 months ago
Haven't seen enough improvement from a previous atopic dermatitis treatment
Don't have any other active skin conditions
Weigh at least 10 kilograms (22 pounds)
If you are interested in having your child participate, the study doctor and team will review additional study criteria with you.
After establishing initial eligibility, study participants will be assigned randomly (by chance) to receive either the study medicine (a tablet taken by mouth) or the comparator, a medicine that’s already been tested in children in this age group with atopic dermatitis (which will be given as an injection under the skin). Your child will be able to take the study medicine as an oral solution if they cannot swallow a tablet. Participants who have previously taken the comparator drug and have not seen improvement will be automatically assigned to receive the study medicine.
Participants taking the study medicine may also be asked to participate in an optional sub-study (a study within the study) to test how the study medicine impacts the effectiveness of certain vaccines, which will be given as injections into the skin. Only children already scheduled to receive these vaccines from another licensed healthcare provider are eligible to participate in the sub-study.
The START-UP Study may last up to 169 weeks (about 3 years) and will consist of up to 22 study visits, 1 of which may be completed over the phone.
This research study is testing a medicine that has already been tested in other age groups.
Do not discontinue any medication unless you are advised to do so by the study clinic staff or your primary care provider.
Clinical research studies are designed in specific ways, and one or more of the answers that you provided were outside of the guidelines for this research study. This does not mean your child will not qualify for different research studies.
Your child may be able to participate in the START-UP Study if they:
Are 6 to under 12 years of age
Were diagnosed with atopic dermatitis at least 6 months ago
Haven't seen enough improvement from a previous atopic dermatitis treatment
Don't have any other active skin conditions
Weigh at least 10 kilograms (22 pounds)
If you are interested in having your child participate, the study doctor and team will review additional study criteria with you.
After establishing initial eligibility, study participants will be assigned randomly (by chance) to receive either the study medicine (a tablet taken by mouth) or the comparator, a medicine that’s already been tested in children in this age group with atopic dermatitis (which will be given as an injection under the skin). Your child will be able to take the study medicine as an oral solution if they cannot swallow a tablet. Participants who have previously taken the comparator drug and have not seen improvement will be automatically assigned to receive the study medicine.
Participants taking the study medicine may also be asked to participate in an optional sub-study (a study within the study) to test how the study medicine impacts the effectiveness of certain vaccines, which will be given as injections into the skin. Only children already scheduled to receive these vaccines from another licensed healthcare provider are eligible to participate in the sub-study.
The START-UP Study may last up to 169 weeks (about 3 years) and will consist of up to 22 study visits, 1 of which may be completed over the phone.
This research study is testing a medicine that has already been tested in other age groups.
Do not discontinue any medication unless you are advised to do so by the study clinic staff or your primary care provider.
Clinical research studies are designed in specific ways, and one or more of the answers that you provided were outside of the guidelines for this research study. This does not mean your child will not qualify for different research studies.
